Search

Your search keyword '"Papayannidis, C"' showing total 397 results
Start Over Author "Papayannidis, C"
397 results on '"Papayannidis, C"'

1. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy

Author

Maurillo, L., Spagnoli, A., Candoni, A., Papayannidis, C., Borlenghi, E., Lazzarotto, D., Fianchi, L., Sciumè, M., Zannier, M.E., Buccisano, F., Del Principe, M.I., Mancini, V., Breccia, M., Fanin, R., Todisco, E., Lunghi, M., Palmieri, R., Fracchiolla, N., Musto, P., Rossi, G., and Venditti, A.

Published
2023
Full Text
View/download PDF

2. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

Author

Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), Foa R., Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), and Foa R.

Abstract

N/A

Published
2024

3. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G, Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, and Martinelli G

Abstract

Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia. Methods: AVALON is a multicentric cohort study that was conducted in Italy on patients with AML who received venetoclax-based therapies from 2015 to 2020. The study was approved by the ethics committee of the participating institution and was conducted in accordance with the Declaration of Helsinki. The effectiveness and toxicity of venetoclax + HMA in 190 (43 newly diagnosed, 68 refractory, and 79 relapsed) patients with AML are reported here. Results: In the newly diagnosed AML, the overall response rate and survival confirmed the brilliant results demonstrated in VIALE-A. In the relapsed or refractory AML, the combination demonstrated a surprisingly complete remission rate (44.1% in refractory and 39.7% in relapsed evaluable patients) and conferred to treated patients a good expectation of survival. Toxicities were overall manageable, and most incidents occurred in the first 60 days of therapy. Infections were confirmed as the most common nonhematologic adverse event. Conclusions: Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax + HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax + HMA effectiveness and toxicities in real life.

Published
2023

4. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic Leukemia

Author

Muschen, Markus, Iacobucci, I, Iraci, N, Messina, M, Lonetti, A, Chiaretti, S, Valli, E, Ferrari, A, Papayannidis, C, Paoloni, F, and Vitale, A

Abstract

Background: Deletions of IKAROS (IKZF1) frequently occur in B-cell precursor acute lymphoblastic leukemia (B-ALL) but the mechanisms by which they influence pathogenesis are unclear. To address this issue, a cohort of 144 adult B-ALL patients (106 BCR-ABL1

Published
2012

5. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, M, Bonifacio, M, Olivi, M, Curti, A, Malagola, M, Dargenio, M, Scattolin, A, Papayannidis, C, Forghieri, F, Gurrieri, C, Tanasi, I, Zappasodi, P, Starza, R, Fracchiolla, N, Chiusolo, P, Giaccone, L, Del Principe, M, Giglio, F, Defina, M, Favre, C, Rizzari, C, Castella, B, Pizzolo, G, Ferrara, F, Chiaretti, S, Foa, R, Cerrano M., Bonifacio M., Olivi M., Curti A., Malagola M., Dargenio M., Scattolin A. M., Papayannidis C., Forghieri F., Gurrieri C., Tanasi I., Zappasodi P., Starza R. L., Fracchiolla N. S., Chiusolo P., Giaccone L., Del Principe M. I., Giglio F., Defina M., Favre C., Rizzari C., Castella B., Pizzolo G., Ferrara F., Chiaretti S., Foa R., Cerrano, M, Bonifacio, M, Olivi, M, Curti, A, Malagola, M, Dargenio, M, Scattolin, A, Papayannidis, C, Forghieri, F, Gurrieri, C, Tanasi, I, Zappasodi, P, Starza, R, Fracchiolla, N, Chiusolo, P, Giaccone, L, Del Principe, M, Giglio, F, Defina, M, Favre, C, Rizzari, C, Castella, B, Pizzolo, G, Ferrara, F, Chiaretti, S, Foa, R, Cerrano M., Bonifacio M., Olivi M., Curti A., Malagola M., Dargenio M., Scattolin A. M., Papayannidis C., Forghieri F., Gurrieri C., Tanasi I., Zappasodi P., Starza R. L., Fracchiolla N. S., Chiusolo P., Giaccone L., Del Principe M. I., Giglio F., Defina M., Favre C., Rizzari C., Castella B., Pizzolo G., Ferrara F., Chiaretti S., and Foa R.

Published
2022

6. A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1 ‐ mutated acute myeloid leukaemia in molecular failure

Author

Sartor, C., primary, Brunetti, L., additional, Audisio, E., additional, Cignetti, A., additional, Zannoni, L., additional, Cristiano, G., additional, Nanni, J., additional, Ciruolo, R., additional, Zingarelli, F., additional, Ottaviani, E., additional, Patuelli, A., additional, Bandini, L., additional, Forte, D., additional, Sciabolacci, S., additional, Cardinali, V., additional, Papayannidis, C., additional, Cavo, M., additional, Martelli, M. P., additional, and Curti, A., additional

Published
2023
Full Text
View/download PDF

7. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Author

de Botton, S, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Ommen, H, Semochkin, S, Kim, H-J, Larson, RA, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, MB, Doronin, V, Doehner, H, Fathi, AT, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, DiNardo, CD, de Botton, S, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Ommen, H, Semochkin, S, Kim, H-J, Larson, RA, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, MB, Doronin, V, Doehner, H, Fathi, AT, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, and DiNardo, CD

Abstract

This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies. Patients were first preselected to a CCR (azacitidine, intermediate-dose cytarabine, low-dose cytarabine, or supportive care) and then randomized (1:1) to enasidenib 100 mg per day or CCR. The primary endpoint was overall survival (OS). Secondary endpoints included event-free survival (EFS), time to treatment failure (TTF), overall response rate (ORR), hematologic improvement (HI), and transfusion independence (TI). Overall, 319 patients were randomized to enasidenib (n = 158) or CCR (n = 161). The median age was 71 years, median (range) enasidenib exposure was 142 days (3 to 1270), and CCR was 36 days (1 to 1166). One enasidenib (0.6%) and 20 CCR (12%) patients received no randomized treatment, and 30% and 43%, respectively, received subsequent AML-directed therapies during follow-up. The median OS with enasidenib vs CCR was 6.5 vs 6.2 months (HR [hazard ratio], 0.86; P = .23); 1-year survival was 37.5% vs 26.1%. Enasidenib meaningfully improved EFS (median, 4.9 vs 2.6 months with CCR; HR, 0.68; P = .008), TTF (median, 4.9 vs 1.9 months; HR, 0.53; P < .001), ORR (40.5% vs 9.9%; P <.001), HI (42.4% vs 11.2%), and red blood cell (RBC)-TI (31.7% vs 9.3%). Enasidenib safety was consistent with prior reports. The primary study endpoint was not met, but OS was confounded by early dropout and subsequent AML-directed therapies. Enasidenib provided meaningful benefits in EFS, TTF, ORR, HI, and RBC-TI in this heavily pretreated older mutant-IDH2 R/R AML population.

Published
2023

8. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Author

Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, Todisco, Elisabetta, Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, and Todisco, Elisabetta

Published
2023

9. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax

Author

Candoni, A., Lazzarotto, D., Papayannidis, C., Piccini, M., Nadali, G., Dargenio, M., Riva, M., Fracchiolla, N., Mellillo, L., Dragonetti, Giulia, Del Principe, M. I., Cattaneo, C., Stulle, M., Pasciolla, C., De Marchi, R., Delia, M., Tisi, M. C., Bonuomo, V., Sciume, M., Spadea, A., Sartor, C., Griguolo, D., Buzzatti, E., Basilico, C. M., Sarlo, C., Piccioni, A. L., Cerqui, E., Lessi, F., Olivieri, A., Fanin, R., Luppi, M., Pagano, Livio, Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Candoni, A., Lazzarotto, D., Papayannidis, C., Piccini, M., Nadali, G., Dargenio, M., Riva, M., Fracchiolla, N., Mellillo, L., Dragonetti, Giulia, Del Principe, M. I., Cattaneo, C., Stulle, M., Pasciolla, C., De Marchi, R., Delia, M., Tisi, M. C., Bonuomo, V., Sciume, M., Spadea, A., Sartor, C., Griguolo, D., Buzzatti, E., Basilico, C. M., Sarlo, C., Piccioni, A. L., Cerqui, E., Lessi, F., Olivieri, A., Fanin, R., Luppi, M., Pagano, Livio, Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

no abstract

Published
2023

10. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study

Author

Lazzarotto, D., Tanasi, I., Vitale, A., Piccini, M., Dargenio, M., Giglio, F., Forghieri, F., Fracchiolla, N., Cerrano, M., Todisco, E., Papayannidis, C., Leoncin, M., Defina, M., Guolo, F., Pasciolla, C., Delia, M., Chiusolo, Patrizia, Mule, A., Candoni, A., Bonifacio, M., Pizzolo, G., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Lazzarotto, D., Tanasi, I., Vitale, A., Piccini, M., Dargenio, M., Giglio, F., Forghieri, F., Fracchiolla, N., Cerrano, M., Todisco, E., Papayannidis, C., Leoncin, M., Defina, M., Guolo, F., Pasciolla, C., Delia, M., Chiusolo, Patrizia, Mule, A., Candoni, A., Bonifacio, M., Pizzolo, G., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

Mixed-phenotype acute leukemia (MPAL) is a rare disease. Treatment is often similar to that of acute lymphoblastic leukemia (ALL), but the outcome in adults and the role of allogeneic stem cell transplantation (AlloSCT) are not well defined. We report on 77 adult patients diagnosed with MPAL over the last 10 years and treated with a curative intent. Median age was 49 years; 7.6% of cases had a BCR::ABL1 rearrangement. Thirty patients (39%) were treated with an acute myeloid leukemia (AML)–like induction and 47 (61%) with an ALL-like scheme. The complete remission (CR) rate was 67.6% and an ALL-like therapy was associated with a better CR rate (P = 0.048). The median OS was 41.9 months; age ≤ 60 years was associated with a better OS (67 vs 26 months, P = 0.014). An AlloSCT was performed in 50 patients (65%). The 5-year OS of transplanted patients was 54%. The OS post-AlloSCT was better in patients who were minimal residual disease (MRD)-negative prior to transplant (75.8% vs 45.2%, P = 0.06). This study shows that MPAL patients respond better to an ALL-like induction therapy; that consolidation therapy should include, whenever possible, an AlloSCT and that MRD negativity should be a primary endpoint of treatment.

Published
2023

11. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Author

Chiaretti, S, Messina, M, Della Starza, I, Piciocchi, A, Cafforio, L, Cavalli, M, Taherinasab, A, Ansuinelli, M, Elia, L, Petroni, G, La Starza, R, Canichella, M, Lauretti, A, Puzzolo, M, Pierini, V, Santoro, A, Spinelli, O, Apicella, V, Capria, S, Di Raimondo, F, De Fabritiis, P, Papayannidis, C, Candoni, A, Cairoli, R, Cerrano, M, Fracchiolla, N, Mattei, D, Cattaneo, C, Vitale, A, Crea, E, Fazi, P, Mecucci, C, Rambaldi, A, Guarini, A, Bassan, R, Foa, R, Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Petroni GA, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, Foa R, Chiaretti, S, Messina, M, Della Starza, I, Piciocchi, A, Cafforio, L, Cavalli, M, Taherinasab, A, Ansuinelli, M, Elia, L, Petroni, G, La Starza, R, Canichella, M, Lauretti, A, Puzzolo, M, Pierini, V, Santoro, A, Spinelli, O, Apicella, V, Capria, S, Di Raimondo, F, De Fabritiis, P, Papayannidis, C, Candoni, A, Cairoli, R, Cerrano, M, Fracchiolla, N, Mattei, D, Cattaneo, C, Vitale, A, Crea, E, Fazi, P, Mecucci, C, Rambaldi, A, Guarini, A, Bassan, R, Foa, R, Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Petroni GA, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, and Foa R

Abstract

Early recognition of Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) cases could impact on the management and outcome of this subset of B-lineage ALL. In order to assess the prognostic value of the Ph-like status in a pediatric-inspired, minimal residual disease (MRD)driven trial, we screened 88 B-lineage ALL cases negative for major fusion genes (BCR-ABL1, ETV6-RUNX1, TCF3-PBX1 and KTM2Ar) enrolled in the GIMEMA LAL1913 front-line protocol for adult BCR/ABL1-negative ALL. The screening - performed using the “BCR/ABL1-like predictor” - identified 28 Ph-like cases (31.8%), characterized by CRLF2 overexpression (35.7%), JAK/STAT pathway mutations (33.3%), IKZF1 (63.6%), BTG1 (50%) and EBF1 (27.3%) deletions, and rearrangements targeting tyrosine kinases or CRLF2 (40%). The correlation with outcome highlighted that: i) the complete remission rate was significantly lower in Ph-like compared to non-Ph-like cases (74.1% vs. 91.5%, P=0.044); ii) at time point 2, decisional for transplant allocation, 52.9% of Ph-like cases versus 20% of non-Ph-like were MRD-positive (P=0.025); iii) the Ph-like profile was the only parameter associated with a higher risk of being MRD-positive at time point 2 (P=0.014); iv) at 24 months, Ph-like patients had a significantly inferior event-free and disease-free survival compared to non-Ph-like patients (33.5% vs. 66.2%, P=0.005 and 45.5% vs. 72.3%, P=0.062, respectively). This study documents that Ph-like patients have a lower complete remission rate, event-free survival and disease-free survival, as well as a greater MRD persistence also in a pediatric-oriented and MRD-driven adult ALL protocol, thus reinforcing that the early recognition of Ph-like ALL patients at diagnosis is crucial to refine risk-stratification and to optimize therapeutic strategies.

Published
2021

12. INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL SEIFEM STUDY ON CLINICAL OUTCOME AND INFECTIOUS COMPLICATIONS IN 230 UNFIT AML PATIENTS TREATED IN FIRST-LINE WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX

Author

Candoni, A, Piccin, M, Lazzarotto, D, Bonuomo, V, Fracchiolla, N, Dargenio, M, Riva, M, Melillo, L, Papayannidis, C, Stulle, M, Lessi, F, Dragonetti, G, Del Principe, M, Cerqui, E, Pasciolla, C, De Marchi, R, Delia, M, Tisi, M, Fanci, R, Nadali, G, Sciume, M, Di Renzo, N, Cairoli, R, Valente, D, Basilico, C, (, C., ), A, (, A., ), D, (, D., ), Pagano, L, Candoni A, Piccin M, Lazzarotto D, Bonuomo V, Fracchiolla N, Dargenio M, Riva M, Melillo L, Papayannidis C, Stulle M, Lessi F, Dragonetti G, Del Principe MI, Cerqui E, Pasciolla C, De Marchi R, Delia M, Tisi MC, Fanci R, Nadali G, Sciume M, Di Renzo N, Cairoli R, Valente D, C (Basilico, C.) 18 Spadea, A (Spadea, A.) 19 Sartor, C (Sartor, C.) 8 Griguolo, D (Griguolo, D.) 9 Sarlo, C (Sarlo, C.) 20 Olivieri, A (Olivieri, A.) 21 Piccioni AL, Pagano L, Candoni, A, Piccin, M, Lazzarotto, D, Bonuomo, V, Fracchiolla, N, Dargenio, M, Riva, M, Melillo, L, Papayannidis, C, Stulle, M, Lessi, F, Dragonetti, G, Del Principe, M, Cerqui, E, Pasciolla, C, De Marchi, R, Delia, M, Tisi, M, Fanci, R, Nadali, G, Sciume, M, Di Renzo, N, Cairoli, R, Valente, D, Basilico, C, (, C., ), A, (, A., ), D, (, D., ), Pagano, L, Candoni A, Piccin M, Lazzarotto D, Bonuomo V, Fracchiolla N, Dargenio M, Riva M, Melillo L, Papayannidis C, Stulle M, Lessi F, Dragonetti G, Del Principe MI, Cerqui E, Pasciolla C, De Marchi R, Delia M, Tisi MC, Fanci R, Nadali G, Sciume M, Di Renzo N, Cairoli R, Valente D, C (Basilico, C.) 18 Spadea, A (Spadea, A.) 19 Sartor, C (Sartor, C.) 8 Griguolo, D (Griguolo, D.) 9 Sarlo, C (Sarlo, C.) 20 Olivieri, A (Olivieri, A.) 21 Piccioni AL, and Pagano L

Published
2021

13. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis

Author

Martinelli, G, Mancini, M, De Benedittis, C, Rondoni, M, Papayannidis, C, Manfrini, M, Meggendorfer, M, Calogero, R, Guadagnuolo, V, Fontana, M C, Bavaro, L, Padella, A, Zago, E, Pagano, L, Zanotti, R, Scaffidi, L, Specchia, G, Albano, F, Merante, S, Elena, C, Savini, P, Gangemi, D, Tosi, P, Ciceri, F, Poletti, G, Riccioni, L, Morigi, F, Delledonne, M, Haferlach, T, Cavo, M, Valent, P, and Soverini, S

Published
2018
Full Text
View/download PDF

15. P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN

Author

Sartor, C., primary, Vigliotta, I., additional, Robustelli, V., additional, Cristiano, G., additional, Nanni, J., additional, Zannoni, L., additional, Parisi, S., additional, Paolini, S., additional, Marconi, G., additional, Martinelli, G., additional, Curti, A., additional, Cavo, M., additional, Terragna, C., additional, and Papayannidis, C., additional

Published
2022
Full Text
View/download PDF

16. P517: PROSPECTIVE MULTICENTRIC STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME IN 230 UNFIT AML PATIENTS TREATED IN FIRST-LINE WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX.

Author

Candoni, A., primary, Piccini, M., additional, Lazzarotto, D., additional, Bonuomo, V., additional, Dargenio, M., additional, Riva, M., additional, Mellillo, L., additional, Papayannidis, C., additional, Stulle, M., additional, Dragonetti, G., additional, Del Principe, M. I., additional, Cattaneo, C., additional, Pasciolla, C., additional, De Marchi, R., additional, Delia, M., additional, Tisi, M. C., additional, Zannier, M. E., additional, Nadali, G., additional, Sciumè, M., additional, Spadea, A., additional, Sartor, C., additional, Griguolo, D., additional, Buzzatti, E., additional, Basilico, C. M., additional, Sarlo, C., additional, Piccioni, A. L., additional, Cairoli, R., additional, Olivieri, A., additional, and Pagano, L., additional

Published
2022
Full Text
View/download PDF

17. P1709: FERTILITY PRESERVATION FOR YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIAS IN ITALY: A CAMPUS ALL SURVEY.

Author

Giglio, F., primary, Bruno, A., additional, Dargenio, M., additional, Cerrano, M., additional, Del Principe, M. I., additional, Forghieri, F., additional, Fumagalli, M., additional, Guolo, F., additional, Imovilli, A., additional, Lunghi, M., additional, Mazzone, C., additional, Papayannidis, C., additional, Pasciolla, C., additional, Trappolini, S., additional, Lazzarotto, D., additional, Bonifacio, M., additional, Candoni, A., additional, Ciceri, F., additional, Pizzolo, G., additional, Vitale, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

18. P357: MULTICENTER RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOME OF ADULT PATIENS WITH MIXED-PHENOTYPE ACUTE LEUKEMIA (MPAL) DIAGNOSED AND TREATED IN THE LAST TEN YEARS. A CAMPUS-ALL STUDY.

Author

Lazzarotto, D., primary, Tanasi, I., additional, Vitale, A., additional, Piccini, M., additional, Dargenio, M., additional, Giglio, F., additional, Forghieri, F., additional, Fracchiolla, N., additional, Cerrano, M., additional, Todisco, E., additional, Papayannidis, C., additional, Leoncin, M., additional, Defina, M., additional, Guolo, F., additional, Pasciolla, C., additional, Delia, M., additional, Chiusolo, P., additional, Mulè, A., additional, Candoni, A., additional, Bonifacio, M., additional, Pizzolo, G., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

19. P1708: PREGNANCIES IN YOUNG ADULTS WITH A HISTORY OF ACUTE LYMPHOBLASTIC LEUKEMIA IN ITALY. A CAMPUS ALL SURVEY.

Author

Giglio, F., primary, Bruno, A., additional, Papayannidis, C., additional, Dargenio, M., additional, Cerrano, M., additional, Forghieri, F., additional, Fumagalli, M., additional, Lunghi, M., additional, Annunziata, M., additional, Bonifacio, M., additional, Ferrara, F., additional, Ciceri, F., additional, Pizzolo, G., additional, Vitale, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

22. P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS

Author

Mancini, M., primary, Monaldi, C., additional, De Santis, S., additional, Papayannidis, C., additional, Rondoni, M., additional, Sartor, C., additional, Bruno, S., additional, Curti, A., additional, Zanotti, R., additional, Bonifacio, M., additional, Scaffidi, L., additional, Pagano, L., additional, Criscuolo, M., additional, Ciceri, F., additional, Elena, C., additional, Tosi, P., additional, Valent, P., additional, Cavo, M., additional, and Soverini, S., additional

Published
2022
Full Text
View/download PDF

23. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, M., Bonifacio, M., Olivi, M., Curti, A., Malagola, M., Dargenio, M., Scattolin, A. M., Papayannidis, C., Forghieri, F., Gurrieri, C., Tanasi, I., Zappasodi, P., Starza, R. L., Fracchiolla, N. S., Chiusolo, Patrizia, Giaccone, L., Del Principe, M. I., Giglio, F., Defina, M., Favre, C., Rizzari, C., Castella, B., Pizzolo, G., Ferrara, F., Chiaretti, S., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Cerrano, M., Bonifacio, M., Olivi, M., Curti, A., Malagola, M., Dargenio, M., Scattolin, A. M., Papayannidis, C., Forghieri, F., Gurrieri, C., Tanasi, I., Zappasodi, P., Starza, R. L., Fracchiolla, N. S., Chiusolo, Patrizia, Giaccone, L., Del Principe, M. I., Giglio, F., Defina, M., Favre, C., Rizzari, C., Castella, B., Pizzolo, G., Ferrara, F., Chiaretti, S., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

n/a

Published
2022

24. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia

Author

Martinelli, G., Papayannidis, C., Piciocchi, A., Robustelli, V., Soverini, S., Terragna, C., Marconi, G., Lemoli, R. M., Guolo, F., Fornaro, A., Lunghi, M., de Fabritiis, P., Candoni, A., Selleri, C., Simonetti, F., Bocchia, M., Vitale, A., Frison, L., Tedeschi, A., Cuneo, A., Bonifacio, M., Martelli, M. P., D'Ardia, S., Trappolini, S., Tosi, P., Galieni, P., Fabbiano, F., Abbenante, M. C., Granier, M., Zhu, Z., Wang, M., Sartor, C., Paolini, S., Cavo, M., Foa, R., Fazi, P., Vignetti, M., and Baccarani, M.

Published
2022

25. INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL SEIFEM STUDY ON CLINICAL OUTCOME AND INFECTIOUS COMPLICATIONS IN 230 UNFIT AML PATIENTS TREATED IN FIRST-LINE WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX

Author

Candoni A, Piccin M, Lazzarotto D, Bonuomo V, Fracchiolla N, Dargenio M, Riva M, Melillo L, Papayannidis C, Stulle M, Lessi F, Dragonetti G, Del Principe MI, Cerqui E, Pasciolla C, De Marchi R, Delia M, Tisi MC, Fanci R, Nadali G, Sciume M, Di Renzo N, Cairoli R, Valente D, Basilico, C (Basilico, C.) 18 Spadea, A (Spadea, A.) 19 Sartor, C (Sartor, C.) 8 Griguolo, D (Griguolo, D.) 9 Sarlo, C (Sarlo, C.) 20 Olivieri, A (Olivieri, A.) 21 Piccioni AL, Pagano L, Candoni, A, Piccin, M, Lazzarotto, D, Bonuomo, V, Fracchiolla, N, Dargenio, M, Riva, M, Melillo, L, Papayannidis, C, Stulle, M, Lessi, F, Dragonetti, G, Del Principe, M, Cerqui, E, Pasciolla, C, De Marchi, R, Delia, M, Tisi, M, Fanci, R, Nadali, G, Sciume, M, Di Renzo, N, Cairoli, R, Valente, D, Basilico, C,, C., ), A,, A., ), D,, D., ), and Pagano, L

Subjects
Hematology
Published
2021

26. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin

Author

Iacobucci, I, Lonetti, A, Candoni, A, Sazzini, M, Papayannidis, C, Formica, S, Ottaviani, E, Ferrari, A, Michelutti, A, Simeone, E, Astolfi, A, Abbenante, M C, Parisi, S, Cattina, F, Malagola, M, Russo, D, Damiani, D, Gherlinzoni, F, Gottardi, M, Baccarani, M, Fanin, R, and Martinelli, G

Published
2013
Full Text
View/download PDF

27. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Author

Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón JA, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, and Cortes JE

Subjects
Acute myeloid leukemia, Clinical trial, Glasdegib, Secondary acute myeloid leukemia, hemic and lymphatic diseases
Abstract

This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized (2:1) patients to receive glasdegib + LDAC (de novo, n = 38; secondary acute myeloid leukemia, n = 40) or LDAC alone (de novo, n = 18; secondary acute myeloid leukemia, n = 20). At the time of analysis, 90% of patients had died, with the longest follow-up since randomization 36 months. The combination of glasdegib and LDAC conferred superior overall survival (OS) versus LDAC alone; hazard ratio (HR) 0.495; (95% confidence interval [CI] 0.325-0.752); p = 0.0004; median OS was 8.3 versus 4.3 months. Improvement in OS was consistent across cytogenetic risk groups. In a post-hoc subgroup analysis, a survival trend with glasdegib + LDAC was observed in patients with de novo acute myeloid leukemia (HR 0.720; 95% CI 0.395-1.312; p = 0.14; median OS 6.6 vs 4.3 months) and secondary acute myeloid leukemia (HR 0.287; 95% CI 0.151-0.548; p < 0.0001; median OS 9.1 vs 4.1 months). The incidence of adverse events in the glasdegib + LDAC arm decreased after 90 days' therapy: 83.7% versus 98.7% during the first 90 days. Glasdegib + LDAC versus LDAC alone continued to demonstrate superior OS in patients with acute myeloid leukemia; the clinical benefit with glasdegib + LDAC was particularly prominent in patients with secondary acute myeloid leukemia. ClinicalTrials.gov identifier: NCT01546038.

Published
2021

28. OUTCOMES OF RELAPSED OR REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT AND VENETOCLAX. THE ITALIAN REAL-LIFE EXPERIENCE BEFORE PUBLIC HEALTH REIMBURSEMENT (AVALON STUDY)

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, Martinelli, G, Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, and Martinelli, G

Published
2021

29. next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome -positive acute lymphoblastic leukemia

Author

Soverini, S, Martelli, M, Bavaro, L, De Benedittis, C, Papayannidis, C, Sartor, C, Sora', Federica, Albano, F, Galimberti, S, Abruzzese, E, Annunziata, M, Russo, S, Stulle, M, Imovilli, A, Bonifacio, M, Maino, E, Stagno, F, Basilico, Cm, Borlenghi, E, Fozza, C, Mignone, F, Minari, R, Stella, S, Baccarani, M, Cavo, M, Martinelli, G, Sora, Federica (ORCID:0000-0002-9607-5298), Soverini, S, Martelli, M, Bavaro, L, De Benedittis, C, Papayannidis, C, Sartor, C, Sora', Federica, Albano, F, Galimberti, S, Abruzzese, E, Annunziata, M, Russo, S, Stulle, M, Imovilli, A, Bonifacio, M, Maino, E, Stagno, F, Basilico, Cm, Borlenghi, E, Fozza, C, Mignone, F, Minari, R, Stella, S, Baccarani, M, Cavo, M, Martinelli, G, and Sora, Federica (ORCID:0000-0002-9607-5298)

Abstract

BCR-ABL1 kinase domain mutation testing in tyrosine kinase inhibitor (TKI)-resistant Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) patients is routinely performed by Sanger sequencing (SS). Recently, next-generation sequencing (NGS)-based approaches have been developed that afford greater sensitivity and straightforward discrimination between compound and polyclonal mutations. We performed a study to compare the results of SS and NGS in a consecutive cohort of 171 Ph+ ALL patients. At diagnosis, 0/44 and 3/44 patients were positive for mutations by SS and NGS respectively. Out of 47 patients with haematologic resistance, 45 had mutations according to both methods, but in 25 patients NGS revealed additional mutations undetectable by SS. Out of 80 patients in complete haematologic response but with BCR-ABL1 ≥0·1%, 28 (35%) and 52 (65%) were positive by SS and NGS respectively. Moreover, in 12 patients positive by SS, NGS detected additional mutations. NGS resolved clonal complexity in 34 patients with multiple mutations at the same or different codons and identified 35 compound mutations. Our study demonstrates that, in Ph+ ALL on TKI therapy, NGS enables more accurate assessment of mutation status both in patients who fail therapy and in patients with minimal residual disease above 0·1%.

Published
2021

30. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR–ABL1-positive acute lymphoblastic leukemia patients

Author

Iacobucci, I, Lonetti, A, Messa, F, Ferrari, A, Cilloni, D, Soverini, S, Paoloni, F, Arruga, F, Ottaviani, E, Chiaretti, S, Messina, M, Vignetti, M, Papayannidis, C, Vitale, A, Pane, F, Piccaluga, P P, Paolini, S, Berton, G, Baruzzi, A, Saglio, G, Baccarani, M, Foà, R, and Martinelli, G

Published
2010
Full Text
View/download PDF

31. IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report: O133

Author

Iacobucci, I., Lonetti, A., Ferrari, A., Vignetti, M., Storlazzi, C. T., Paoloni, F., Cilloni, D., Soverini, S., Vitale, A., Chiaretti, S., Cimino, G., Astolfi, A., Testoni, N., Papayannidis, C., Paolini, S., Piccaluga, PP., Elia, L., Messa, F., DellʼAgnola, C., Cingarlini, S., Meloni, G., Leone, G., Amadori, S., Russo, D., Saglio, G., Pane, F., Baccarani, M., Foà, R., and Martinelli, G.

Published
2009

32. pH-positive acute lymphoblastic leukaemia is characterised by recurrent copy number anomalies in genes regulating the cell cycle and B-cell differentiation: O138

Author

Iacobucci, I., Ottaviani, E., Lonetti, A., Ferrari, A., Astolfi, A., Storlazzi, CT., Testoni, N., Paolini, S., Papayannidis, C., Cilloni, D., Messa, F., Soverini, S., Arruga, F., Pane, F., Vitale, A., Messina, M., Chiaretti, S., Piccaluga, PP., DellʼAgnola, C., Cingarlini, S., Foà, R., Baccarani, M., and Martinelli, G.

Published
2009

34. PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS

Author

Mancini, M., primary, Monaldi, C., additional, De Santis, S., additional, Papayannidis, C., additional, Rondoni, M., additional, Bavaro, L., additional, Martelli, M., additional, Ficarra, E., additional, Paciello, G., additional, Fontana, M.C., additional, Zanotti, R., additional, Pagano, L., additional, Albano, F., additional, Ciceri, F., additional, Elena, C., additional, Tosi, P., additional, Delledonne, M., additional, Valent, P., additional, Martinelli, G., additional, Cavo, M., additional, and Soverini, S., additional

Published
2019
Full Text
View/download PDF

35. PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE

Author

Paolini, S., primary, Romani, L., additional, Ottaviani, E., additional, Marconi, G., additional, Papayannidis, C., additional, Parisi, S., additional, Sartor, C., additional, Nanni, J., additional, Cristiano, G., additional, Abbenante, M. C., additional, Talami, A., additional, Olivi, M., additional, Ragaini, S., additional, Bandini, L., additional, Venturi, C., additional, Raffini, M., additional, Robustelli, V., additional, Martinelli, G., additional, Testoni, N., additional, Baldazzi, C., additional, Cavo, M., additional, and Curti, A., additional

Published
2019
Full Text
View/download PDF

36. PS976 METABOLIC REPROGRAMMING OF ACUTE MYELOID LEUKEMIA STEM- PROGENITOR CELLS AT RELAPSE

Author

Ghetti, M., primary, Padella, A., additional, Pazzaglia, M., additional, De Tommaso, R., additional, Fontana, M., additional, Bruno, S., additional, Bochicchio, M.T., additional, Ferrari, A., additional, Napolitano, R., additional, Franchini, E., additional, Nanni, J., additional, Marconi, G., additional, Papayannidis, C., additional, Remondini, D., additional, Martinelli, G., additional, and Simonetti, G., additional

Published
2019
Full Text
View/download PDF

37. PS931 ADULT TRIPLE NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA FUSION DETECTION: CHALLENGING AIM FOR PH- ALTERNATIVE THERAPIES

Author

Ferrari, A., primary, Vitali, S., additional, Baldazzi, C., additional, Ferrari, G., additional, Robustelli, V., additional, Luserna Di Rora, A. Ghelli, additional, Fonzi, E., additional, Tebaldi, M., additional, Salvi, S., additional, Papayannidis, C., additional, Paolini, S., additional, Padella, A., additional, Bochicchio, M., additional, Marconi, G., additional, Imbrogno, E., additional, Pasquini, G., additional, Santoro, A., additional, Hernández-Rivas, J., additional, Calistri, D., additional, Castellani, G., additional, Testoni, N., additional, Remondini, D., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

38. S1620 NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.

Author

Candoni, A., primary, Lazzarotto, D., additional, Curti, A., additional, Ferrara, F., additional, Lussana, F., additional, Papayannidis, C., additional, Del Principe, M.I., additional, Bonifacio, M., additional, Mosna, F., additional, Delia, M., additional, Minetto, P., additional, Gottardi, M., additional, Fracchiolla, N., additional, Mancini, V., additional, Forghieri, F., additional, Zappasoldi, P., additional, Cerrano, M., additional, Vitale, A., additional, Audisio, E., additional, Trappolini, S., additional, Romani, C., additional, Defina, M., additional, Imbergamo, S., additional, Ciccone, N., additional, Santoro, L., additional, Cambò, B., additional, Iaccarino, S., additional, Dargenio, M., additional, Aprile, L., additional, Pizzolo, G., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

39. PB1726 DOUBLE FLUDARABINE-BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE.

Author

Sartor, C., primary, De Polo, S., additional, Lewis, R.E., additional, Marconi, G., additional, Abbenante, M., additional, Nanni, J., additional, Talami, A., additional, Olivi, M., additional, Bertamini, L., additional, Ragaini, S., additional, Paolini, S., additional, Parisi, S., additional, Cristiano, G., additional, Ottaviani, M., additional, Bandini, L., additional, Fontana, M.C., additional, Martinelli, G., additional, Curti, A., additional, Papayannidis, C., additional, Cavo, M., additional, and Stanzani, M., additional

Published
2019
Full Text
View/download PDF

40. PS1029 CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

Author

Heuser, M., primary, Fiedler, W., additional, Sekeres, M.A., additional, Montesinos, P., additional, Leber, B., additional, Merchant, A., additional, Papayannidis, C., additional, Pérez-Simón, J.A., additional, Hoang, C.J., additional, Ma, W.W., additional, Zeremski, M., additional, O’Connell, A., additional, Chan, G., additional, and Cortes, J.E., additional

Published
2019
Full Text
View/download PDF

41. PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Author

Soverini, S., primary, Martelli, M., additional, Bavaro, L., additional, Papayannidis, C., additional, Sica, S., additional, Sorà, F., additional, Albano, F., additional, Galimberti, S., additional, Barate’, C., additional, Rondoni, M., additional, Abruzzese, E., additional, Annunziata, M., additional, Russo, S., additional, Mannina, D., additional, Stulle, M., additional, Imovilli, A., additional, Curti, A., additional, Bonifacio, M., additional, Ferrero, D., additional, Basilico, C., additional, Reddiconto, G., additional, Mineo, G., additional, Laginestra, M.A., additional, Pileri, S.A., additional, Mignone, F., additional, Percesepe, A., additional, Martinelli, G., additional, and Cavo, M., additional

Published
2019
Full Text
View/download PDF

42. PS1035 GEMTUZUMAB OZOGAMICINE-BASED SALVAGE THERAPIES IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS

Author

Segura, S. Jaramillo, primary, Montesinos, P., additional, Venditti, A., additional, Papayannidis, C., additional, Kayser, S., additional, Martinez-cuadrón, D., additional, Paterno, G., additional, Serrano, J., additional, Polo, M., additional, García-Boyero, R., additional, Müller-Tidow, C., additional, and Schlenk, R.F., additional

Published
2019
Full Text
View/download PDF

43. PS928 “3C-UP” A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP: NOVEL MOLECULAR MARKERS

Author

Ferrari, A., primary, Vitali, S., additional, Robustelli, V., additional, Luserna di Rorà, A. Ghelli, additional, Baldazzi, C., additional, Righi, S., additional, Fonzi, E., additional, De Matteis, S., additional, Ghetti, M., additional, Napolitano, R., additional, Tebaldi, M., additional, Salvi, S., additional, Papayannidis, C., additional, Marconi, G., additional, Paolini, S., additional, Ferrari, G., additional, Fontana, M., additional, Imbrogno, E., additional, Padella, A., additional, Simonetti, G., additional, Pasquini, G., additional, Santoro, A., additional, Hernández-Rivas, J., additional, Calistri, D., additional, Castellani, G., additional, Sabattini, E., additional, Testoni, N., additional, Remondini, D., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

44. PS1020 SNP ARRAY REVEALS A NEW DELETION OF JAK2 IN AML PATIENTS

Author

Cerchione, C., primary, Guadagnuolo, V., additional, Papayannidis, C., additional, Fontana, M.C., additional, Padella, A., additional, Iacobucci, I., additional, Simonetti, G., additional, Marconi, G., additional, Paolini, S., additional, Abbenante, M., additional, Parisi, S., additional, Volpato, F., additional, Ottaviani, E., additional, Delledonne, M., additional, Biasco, G., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

45. PF292 LOW-DOSE CYTARABINE WITH OR WITHOUT GLASDEGIB IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

Author

Papayannidis, C., primary, Smith, B.D., additional, Heuser, M., additional, Montesinos, P., additional, Sekeres, M.A., additional, Oriol, A., additional, Schiller, G., additional, Candoni, A., additional, Jamieson, C., additional, Hoang, C., additional, Ma, W.W., additional, Zeremski, M., additional, O’Connell, A., additional, Chan, G., additional, and Cortes, J., additional

Published
2019
Full Text
View/download PDF

46. PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1

Author

Cerchione, C., primary, Guadagnuolo, V., additional, Papayannidis, C., additional, Iacobucci, I., additional, Padella, A., additional, Simonetti, G., additional, Paolini, S., additional, Abbenante, M., additional, Parisi, S., additional, Volpato, F., additional, Fontana, M.C., additional, Ottaviani, E., additional, Testoni, N., additional, Baldazzi, C., additional, Delledonne, M., additional, Filì, C., additional, Malagola, M., additional, Cattina, F., additional, Bernardi, S., additional, Russo, D., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

47. PF197 A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS

Author

Simonetti, G., primary, Padella, A., additional, Mengucci, C., additional, Fonzi, E., additional, Picone, G., additional, Pazzaglia, M., additional, Perricone, M., additional, Fontana, M., additional, Bruno, S., additional, Bochicchio, M.T., additional, Franchini, E., additional, Nanni, J., additional, Marconi, G., additional, do Valle, I.F., additional, De Tommaso, R., additional, Ferrari, A., additional, Ghetti, M., additional, Napolitano, R., additional, Papayannidis, C., additional, Ghelli Luseran di Rorà, A., additional, Cerchione, C., additional, Ottaviani, E., additional, Castellani, G., additional, Remondini, D., additional, Capozzi, F., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

48. PS1461 FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES

Author

Tanasi, I., primary, Bonifacio, M., additional, Pizzolato, M., additional, Grifoni, F.I., additional, Sciumè, M., additional, Elena, C., additional, Benvenuti, P., additional, Mannelli, F., additional, Parente, R., additional, Schena, D., additional, Scaffidi, L., additional, Bonadonna, P., additional, Papayannidis, C., additional, Rondoni, M., additional, Criscuolo, M., additional, Vannucchi, A.M., additional, Triggiani, M., additional, Martinelli, G., additional, Krampera, M., additional, and Zanotti, R., additional

Published
2019
Full Text
View/download PDF

49. Chromothripsis in acute myeloid leukemia: Biological features and impact on survival

Author

Fontana, M C, primary, Marconi, G, additional, Feenstra, J D M, additional, Fonzi, E, additional, Papayannidis, C, additional, di Rorá, A G L, additional, Padella, A, additional, Solli, V, additional, Franchini, E, additional, Ottaviani, E, additional, Ferrari, A, additional, Baldazzi, C, additional, Testoni, N, additional, Iacobucci, I, additional, Soverini, S, additional, Haferlach, T, additional, Guadagnuolo, V, additional, Semerad, L, additional, Doubek, M, additional, Steurer, M, additional, Racil, Z, additional, Paolini, S, additional, Manfrini, M, additional, Cavo, M, additional, Simonetti, G, additional, Kralovics, R, additional, and Martinelli, G, additional

Published
2017
Full Text
View/download PDF

50. Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients

Author

De Benedittis C, Soverini S, Machova Polakova K, Brouckova A, Rosti G, Castagnetti F, Gugliotta G, Papayannidis C, Klamova H, Iacobucci I, Russo D, Martínez Lopez J, Barrio S, Baccarani M, Cavo M, Martinelli G, and De Benedittis C, Soverini S, Machova Polakova K, Brouckova A, Rosti G, Castagnetti F, Gugliotta G, Papayannidis C, Klamova H, Iacobucci I, Russo D, Martínez Lopez J, Barrio S, Baccarani M, Cavo M, Martinelli G

Subjects
bcr-abl35-in, truncation, Deep sequencing, chronic myeloid leukemia, bcr-abl kinase domain mutation, Philadelphia positive acute lymphoblastic leukemia, insertion
Published
2014

Catalog

Books, media, physical & digital resources
See catalog results